The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up

by Melly Alazraki on Feb.09, 2011, under Towing

To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.

Continue reading The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up

The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up originally appeared on DailyFinance on Wed, 09 Feb 2011 20:00:00.

Filed Under: Health Care, Genzyme Corporation , GlaxoSmithKline, Novartis, Amgen, Eli Lilly